TGF-β1 [52], TIMP-2 [53], and VEGFR-2 [54] have been recognized in a number of studies as the key regulators of fibrogenesis and angiogenesis, which determined the choice of these biomarkers for detecting the effects of breast cancer treatment. This evidence concerns the gene TIMP2 and breast carcinoma.